NASDAQ · DGX
Healthcare · Medical - Diagnostics & Research
$240.30
Down-$2.46 (-1.01%)
Updated Sep 1, 2026, 4:37 AM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 21 trading sessions · Daily adjusted prices
DGX closed at $240.30 after 21 trading sessions, up 3.60% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 31, 2026 | $241.99 | $242.635 | $239.40 | $240.30 | 1.39M |
| Aug 28, 2026 | $245.17 | $245.28 | $242.27 | $242.76 | 639.94K |
| Aug 27, 2026 | $242.83 | $247.19 | $242.44 | $244.61 | 839.99K |
| Aug 26, 2026 | $244.11 | $246.00 | $243.485 | $245.00 | 811.02K |
| Aug 25, 2026 | $243.93 | $245.78 | $241.79 | $244.51 | 709.15K |
| Aug 24, 2026 | $243.97 | $246.00 | $242.455 | $243.87 | 837.74K |
| Aug 21, 2026 | $240.33 | $244.70 | $239.43 | $244.39 | 1.26M |
| Aug 20, 2026 | $239.86 | $245.675 | $237.525 | $241.30 | 1.14M |
| Aug 19, 2026 | $238.10 | $242.39 | $237.38 | $241.76 | 924.01K |
| Aug 18, 2026 | $238.01 | $239.38 | $236.07 | $236.25 | 693.61K |
| Aug 17, 2026 | $233.94 | $237.168 | $233.00 | $235.52 | 614.27K |
| Aug 14, 2026 | $235.82 | $237.695 | $233.685 | $234.40 | 541.8K |
| Aug 13, 2026 | $239.10 | $240.00 | $235.65 | $236.04 | 549.03K |
| Aug 12, 2026 | $234.46 | $238.51 | $232.28 | $237.77 | 686.87K |
| Aug 11, 2026 | $236.35 | $239.92 | $235.51 | $237.50 | 847.03K |
| Aug 10, 2026 | $236.53 | $239.33 | $235.85 | $237.63 | 856.19K |
| Aug 7, 2026 | $236.34 | $239.375 | $236.34 | $238.35 | 574.52K |
| Aug 6, 2026 | $237.66 | $238.88 | $235.315 | $238.50 | 642.22K |
| Aug 5, 2026 | $234.22 | $236.665 | $232.56 | $235.84 | 674.2K |
| Aug 4, 2026 | $231.95 | $234.545 | $229.755 | $233.72 | 904K |
| Aug 3, 2026 | $232.84 | $233.435 | $230.54 | $231.95 | 839.25K |
The latest Smart Investors Daily articles mentioning DGX.
DGX research
Company profile and research snapshot.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 28, 2026 | JP Morgan | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
| Jul 24, 2026 | Baird | Neutral | — |
| Jul 24, 2026 | Truist Securities | Hold | — |
| Jul 24, 2026 | Mizuho | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 24, 2026
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patientsQuest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10%
Yahoo · Aug 21, 2026
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
Yahoo · Aug 20, 2026
Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...
Yahoo · Aug 20, 2026
Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DGX.
